Genomic evolution of *Bordetella pertussis* and post-COVID-19 resurgence of pertussis: insights from a global multi-country study

Haodong Zhang BSc[a,b,1], Zhihua Kang M.D.[c,1], Yingying Zhang PhD[d,1], Yuanbin Yang BSc[e,1], Huiwen Li BSc[a,b], Naike Wang BSc[f], Jiancheng Wang BSc[f], Fuxiang Jiao BSc[f], Shanwei Tong BSc[f], Bingsong Wang M.S.[g], Song Gao PhD[h], Chengpei Ni PhD[h], Xiaolu Shi PhD[i], Shuang Wu PhD[i], Simo Huang M.D.[j], Danni Bao PhD[k], Qiushui He MD, PhD[l,m,n], Chuanqing Wang MD [a,b], Zhi Ruan PhD[d,o,p*], Pan Fu M.D.[a,b*], Chao Yang PhD[f,*]

[a.] Laboratory of Microbiology, Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[b.] Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[c.] Department of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

[d.] Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

[e.] Department of Microbiological Testing, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China

[f.] Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

[g.] Pediatric Respiratory Department, Wuhu No.1 People's Hospital, Wuhu, Anhui, China.

[h.] The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi, China

[i] Shenzhen Center for Disease Control and Prevention, Shenzhen, China;

[j.] Department of Clinical Laboratory, Seventh Medical Center, PLA General Hospital, Beijing, China;

[k.] Department of Clinical Laboratory, Sanmen People's Hospital, Taizhou, China;

[l.] Institute of Biomedicine, University of Turku, Turku, Finland;

[m.] InFLAMES Research Flagship Centre, University of Turku, Turku, Finland;

[n.] European Union (EU) Reference Laboratory for Diphtheria & Pertussis (EURL-PH-DIPE), Turku, Finland;

[o.] Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, China;

p. Zhejiang Provincial Engineering Research Center of Innovative Instruments for Precise Pathogen

Detection, Hangzhou, China

[1] Those authors contribute equally

*Correspondence

Zhi Ruan, Email: r_z@zju.edu.cn

Pan Fu, Email: fup1028@163.com

Chao Yang, Email: cyang@siii.cas.cn

Summary

Background

A global resurgence of pertussis has occurred following the COVID-19 pandemic, yet the

underlying drivers behind remain unclear. We aimed to investigate the role of *Bordetella*

pertussis genomic evolution in the post-pandemic resurgence.

Methods

We integrated global purtussis surveillance data with 8117 genomic sequences of *B pertussis*

isolated from 35 countries across six continents. Temporal dynamics in *B pertussis* genotypes,

antigenic profiles and macrolide resistance before, during, and after the COVID-19 pandemic

were analyzed.

Findings

Substantial post-pandemic shifts in *B pertussis* populations were observed in China and

Australia. In China, the resurgence was driven by the rapid expansion of a single, recently

emerged macrolide-resistant *B pertussis* (MRBP) clone, MR-MT28 (*ptxP3/fim3-1/prn150* or

pertactin (PRN)-deficient), which replaced pre-existing strains. In Australia, MR-MT28

strains were introduced and expanded post-pandemic, with MRBP accounting for 23% (9/40)

of sequenced genomes, along with a shift towards *ptxP3/fim3-2/prn2* genotypes and a decline

in frequency of PRN-deficient strains. In Europe, a convergent post-pandemic rise in the *prn2*

allele frequency together with significant decline in frequency of PRN-deficient strains was

observed. In addition, macrolide resistant strains (*ptxP3/fim3-1*/PRN-deficicent) emerged in

2024 in several European countries. Moreover, the MR-MT28 clone has been detected post-

pandemic in four countries/continents (China, Australia, France, and the United States), with

most isolates outside China (72%, 8/11) belonging to a PRN-deficient subclone.

Interpretation

The convergent and region-specific strain replacement and antigenic variation together with

emergence of macrolide resistance post-pandemic suggest a key role for *B pertussis* adaptive

evolution in the global pertussis resurgence. The emergence and international dissemination

of the MR-MT28 strains represent a growing public health concern, highlighting the urgent

need for coordinated global surveillance.

Funding

National Key Research and Development Program of China, National Natural Science

Foundation of China, Youth Innovation Promotion Association, Chinese Academy of

Sciences, Shanghai Rising-Star Program, Zhejiang Provincial Science and Technology

Program for Disease Prevention and Control, Sigrid Juselius Foundation and Tampere

Tuberculosis Foundation.

Key words: pertussis, *Bordetella pertussis*, resurgence, COVID-19, MR-MT28

Research in context

Evidence before this study

We searched PubMed for studies on the molecular epidemiology of pertussis resurgence

following the COVID-19 pandemic using the terms ("*Bordetella pertussis*" OR "pertussis"

OR "whooping cough") AND ("resurgence" OR "upsurge") for articles published between

January 2022 and May 2025. A total of 92 relevant publications were identified. Among them,

33 studies described the resurgence of pertussis during or after the COVID-19 pandemic, but

most focused on individual countries, including China, Finland, South Korea, and France.

Only six studies used whole-genome sequencing to investigate the resurgence at the genomic

level, with four focusing on China, one on France, and one on Australia. However, no study

has provided an integrated analysis of the dynamics of circulating *B pertussis* strains and the

rising incidence of pertussis before, during, and after the pandemic at a global level. As a

result, the relationship between *B pertussis* evolution and the recent global resurgence of

pertussis remains poorly understood.

Added value of this study

This study represents the first global genomic investigation of *B pertussis* dynamics in the

context of the global post-pandemic resurgence. We identified convergent and region-specific

changes in *B pertussis* population and genetic variation associated with antibiotic resistance,

vaccine escape, and virulence across continents. We demonstrate that in China, the resurgence

was most likely driven by the expansion of a single macrolide-resistant clone (MR-MT28),

while in Australia and several European countries, post-pandemic shifts in antigenic profiles

(e.g., rise in *prn2*, decline in PRN-deficient strains) and emerging macrolide resistance were

observed. Notably, we report post-pandemic international dissemination (identified across

four continents) and ongoing evolution of the MR-MT28 clone by reconstructing its

evolutionary dynamics and global spread patterns.

Implications of all the available evidence

Our findings suggest that adaptive evolution of *B pertussis* is a key contributor to the post-

pandemic global resurgence of pertussis. The emergence and international spread of MR-

MT28 strains raise additional concerns regarding potential treatment failures associated with

resistant pertussis infections, and represent a growing public health concern, highlighting the

urgent need for coordinated global surveillance.

Introduction

Pertussis, a highly contagious respiratory disease primarily caused by *Bordetella pertussis*,

declined globally following the introduction of whole-cell and acellular vaccines.[1,2] Despite

sustained high vaccination coverage, many countries have observed a resurgence over the past

two decades, with a marked increase post-COVID-19 pandemic.[3–5]

According to the World Health Organization (WHO), following a sharp decline during the

COVID-19 pandemic (2020–2022), global pertussis cases rose substantially post-pandemic

(2023–2024), exceeding 800,000 notifications worldwide in 2024 —over at least four times

higher than the pre-pandemic average (**figure 1A**). In Asia, China and South Korea

reported >10-fold and >20-fold increases, respectively.[6–8] Several European countries,

including France, Czechia and Denmark, recorded historically high incidence.[9–12] Similar

surges were observed in Australia[13] and the United States[4] (**figure 1B**).

Multiple factors underlie this resurgence, including immunity debt from pandemic-related

non-pharmaceutical interventions, waning vaccine-induced immunity, and adaptive evolution

of *Bordetella pertussis*.[2–7] Over recent decades, *B pertussis* has undergone notable genetic

shifts, including the emergence and prevalence of strains with *ptxP3* alleles potentially

associated with increased virulence,[14] and pertactin (PRN)-deficient variants, which may

evade vaccine-induced immunity.[15] In parallel, the emergence of macrolide-resistant *B

pertussis* (MRBP), particularly its predominance in China, has raised additional concern

regarding potential transmission and treatment failures.[16–19]

Of particular concern is the *ptxP3* MR-MT28 clone. It has been proposed as a major driver of

China's post-pandemic resurgence due to its combined features of vaccine escape and

antimicrobial resistance.[18,20] Notably, this clone has been recently detected in France[11,12] and

Australia,[13] raising concerns of international dissemination. Although the post-pandemic

resurgence of pertussis in China appears closely associated with the expansion of the MR-

MT28 clone, integrated analyses of dynamics of circulating *B pertussis* strains and rising

incidence of pertussis before, during and after the pandemic at global level have been not

performed.

In this study, we investigated the genomic evolution of *B pertussis* in the context of the global

post-pandemic resurgence. We found that lineage composition, vaccine antigen profiles, and

MRBP prevalence underwent substantial shifts in several regions in parallel with the rising

pertussis burden, providing evidence that adaptive evolution of *B pertussis* is one key

contributor to the recent global resurgence. Our analysis highlights that the MR-MT28 clone,

which drove the post-pandemic resurgence in China, has now spread to other three continents,

underscoring the urgent need for coordinated global surveillance.

Methods

Pertussis case data

Pertussis case numbers were obtained from the WHO website

(https://immunizationdata.who.int/global/wiise-detail-page/pertussis-reported-cases-and-

incidence). For countries or regions with incomplete WHO data, supplementary case counts

were searched and sourced from national public health agencies, including the US Centers for

Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and

Control (ECDC).

Genome collection and sequencing

We analysed a total of 8,368 non-redundant *B pertussis* genomes with unique Biosample

accession numbers, comprising 8112 publicly available genomes and 249 newly sequenced

isolates. Public genomes were retrieved from the NCBI Sequence Read Archive (SRA) and

GenBank, with isolation year and country extracted from BioSample metadata. Newly

sequenced isolates were collected from six regions in China: Shanghai (n=42), Zhejiang

(n=165), Anhui (n=7), Jiangsu (n=3), Sichuan (n=19), and Guangdong (n=13). Whole-

genome sequencing for newly sequenced isolates was performed on the Illumina NovaSeq

platform. Newly generated sequencing data are available in the NCBI SRA under accession

number PRJNA1288341.

Raw sequencing reads were quality-trimmed using Trimmomatic v0.39.[21] Genome assembly

was conducted using the shovill v1.1.0 pipeline (https://github.com/tseemann/shovill).

Assembly quality was assessed using CheckM v1.1.3.[22] Only high-quality genomes

(completeness >95%, contamination <5%) were retained in following analysis. Putative

mutator strains indicated by abnormal tree branches were also removed from analysis.

After genome quality control, a total of 8117 high-quality genomes (appendix p4,

supplementary table 1) were used in the analysis, includes isolates collected between 1900

and 2024 from 35 countries across six continents: Europe (16 countries), Asia (6), North

America (5), Africa (4), Oceania (2), and South America (2).

Phylogenetic and temporal analysis

Core-genome single nucleotide polymorphisms (SNPs) were identified using Snippy v4.6.0

(https://github.com/tseemann/snippy), based on raw reads or assemblies where reads were

unavailable, with *B pertussis* Tohama I (NC_002929.2) as the reference. SNPs within

repetitive regions were excluded as previously described.[23] Maximum-likelihood phylogenies

were constructed using FastTree v2.1.10[24] (all strains) or RAxML-NG v1.0.1[25] with the

GTR+Γ model (MR-MT28 clone).

Time-resolved phylogenies and effective population size dynamics were inferred using

BEAST v1.10.4.[26] We applied GTR+Γ substitution model and used isolation date (years) for

tip date calibration. Six combinations of molecular clocks (strict and uncorrelated relaxed

clock) and coalescent tree models (constant size and Bayesian Skyline and Skygrid) were

tested and Skygrid model were the best fit based on path sampling and steppingstone

sampling analysis. We ran ten independent Markov chain Monte Carlo chains for 30 million

steps, sampling every 3,000 steps. The results of different runs were combined to generate the

maximum clade credibility trees using TreeAnnotator v1.10.4. Effective population size

dynamics was inferred using Tracer v1.7.1.[27]

Vaccine antigen and macrolide resistance profiles

Vaccine antigen alleles were assigned by comparison with the curated *Bordetella* allele

database on BIGSdb-Pasteur.[28] So far the only mechanism causing macrolide resistance has

been the point mutation of A2047G in the 23S rRNA gene of *B pertussis*. Therefore, MRBP

strains carrying the A2047G mutation were detected using BLASTn. Strains were classified

as PRN-deficient if they carried incomplete or disrupted *prn* coding sequences or promoters

(BLASTn or TBLASTn coverage <99%), based on criteria defined by Lefrancq et al.[29]

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data

interpretation, or writing of the report.

Results

Global genomic diversity and population structure of *B pertussis*

We analysed 8,117 high-quality genomes, including 249 newly sequenced strains from six

regions in China. These genomes spanned 35 countries across six continents. Four continents

and five countries each had more than ten genomes from both pre-pandemic and during/post-

pandemic periods, enabling temporal and geographical comparisons (**figure 2A**; appendix p2,

supplementary figure 1).

A core-genome SNP-based phylogenetic tree was constructed to characterise the global

population structure of *B pertussis* (**figure 2B**). The phylogentic tree revealed that 99.6%

(8087/8117) of isolates belonged to lineage IIb,[30] which could be further divided into three

major sublineages based on *ptxP* and *fim3* genotypes: *ptxP1/fim3-1* (17%, n=1364),

ptxP3/fim3-1 (60%, n=4812), and *ptxP3/fim3-2* (22%, n=1816). The difference between *fim3-*

1 and *fim3-2* alleles is a point mutation of C260A causing an amino acid change (Ala87Glu),

and the difference between *ptxP1* and *ptxP3* is a point mutation of C to A in promoter of

pertussis toxin gene.

The MRBP-associated A2047G mutation in 23S rRNA gene were detected in 59% (811/1364)

of *ptxP1/fim3-1*, 11% (519/4812) of *ptxP3/fim3-1* and 0.3% (5/1817) of *ptxP3/fim3-2* strains.

Nearly all (99%, 513/519) *ptxP3/fim3-1* MRBP strains belonged to the MR-MT28 clone

(**figure 2B**), which was predominantly identified in China.[20]

Lineage dynamics and variation in vaccine antigen and antibiotic resistance profiles

Post-pandemic increases in pertussis were accompanied by convergent and region-specific

shifts in lineage composition, vaccine antigen profiles, and macrolide resistance (**figure 3,**

appendix p3, supplementary figure 2).

In Asia (n=2023), primarily represented by China (n=1645), the *ptxP3/fim3-1* sublineage

expanded rapidly during and after the pandemic, alongside a marked rise in MRBP frequency

and substantial shifts in antigen profiles (**figure 3**). This transition was driven by the

emergence and rapid expansion of the MR-MT28 clone. MR-MT28 (n=513) carried either

ptxP3/fim3-1/prn150 (74%, 382/513) or *ptxP3/fim3-*1 with predicted PRN-deficiency (25%,

129/513) profiles, becoming the dominant clone (99%) post-pandemic in China (**figure 2B,**

figure 3). This clonal replacement also shifted the MRBP composition, from a pre-pandemic

predominance of *ptxP1/fim3-1* strains (87%, 774/891) to *ptxP3/fim3-1* (92%, 386/418) post-

pandemic (**figure 3B**). In line with the dominance of a single clone, the genetic diversity of

post-pandemic strains (median SNP distance: 8) was significantly decreased compared to that

of pre-pandemic strains (median SNP distance: 31; **figure 2C**).

Similarly, in Oceania (n=489), mainly represented by Australia (n=445), substantial post-

pandemic shifts were observed in sublineage distribution and antigen gene composition,

accompanied by an increase in MRBP prevalence (**figure 3**). Based on this genomic analysis,

MRBP prevalence notably reached 23% (9/40) post-pandemic—an unexpectedly high

frequency given the previous rarity of MRBP outside China,[19] and this rise was also

associated with the introduction of the MR-MT28 clone. Unlike Asia, changes in sublineage

and antigen gene profiles were largely driven by the rise of *ptxP3/fim3-2* sublineage and *fim3-*

2 and *prn2* alleles, along with a decreased frequency of predicted PRN-deficient strains

(**figure 3**).

Post-pandemic strains in Oceania remained genetically diverse, with *ptxP3/fim3-2* and

ptxP3/fim3-1 sublineages present at 45% (18/40) and 53% (21/40), respectively. Accordingly,

genetic diversity remained relatively stable post-pandemic. Phylogenetic analysis showed that

close relatives of most post-pandemic strains were already circulating before the pandemic,

with the exception of MR-MT28, suggesting that the resurgence in Oceania might be driven

by the expansion of locally pre-existing lineages (**figures 2B, figure 3**).

In Europe (n=2595), mainly represented by France (n=1308) and Belgium (n=429), noticeable

post-pandemic changes were observed in the vaccine antigen gene *prn*. As in Australia, the

frequency of the *prn2* allele increased post-pandemic, while the frequency of predicted PRN-

deficient strains decreased (**figure 3**). One MR-MT28 strain was detected in France in 2024.

Overall genetic diversity in Europe did not significantly decline post-pandemic, although two

dominant clones (Europe clone 1 and 2, accounting for 65% of post-pandemic strains) were

identified (**figure 2B**). Both clones were already present pre-pandemic, indicating continued

transmission of locally endemic strains. However, this varied by country—for instance, post-

pandemic strains in Belgium showed significantly reduced diversity, with 70% (64/91)

belonging to Europe clone 2 (**figure 2B,C**).

In North America (n=2,832), primarily represented by the United States (n=2,798), strain

dynamics remained relatively stable. The North America clone 1, prevalent pre-pandemic,

remained dominant post-pandemic (67%, 69/103), continuing to drive endemic circulation

(**figure 2B**). One MR-MT28 strain was identified in the United States in 2024.

Evolutionary dynamics and global spread of the MR-MT28 clone

The MR-MT28 clone was detected in four countries (China, Australia, France, and the United

States) across four continents post-pandemic (**figure 4A, B**), indicating its potential for global

dissemination. We therefore investigated its evolutionary origin and patterns of international

spread.

Phylogenetic analysis suggested that MR-MT28 evolved from the MS-MT28 lineage, which

was primarily identified in Europe and North America pre-pandemic (**figure 4C, D**).

Although MR-MT28 has become dominant in eastern China post-pandemic, it remains at

relatively low frequency in western regions (**figure 4B**). Molecular clock analysis estimated

the emergence of MR-MT28 around 2016 (95% CI: 2014–2018), most likely originating in

China, where it now predominates. Consistent with the observed rise in MR-MT28 cases and

its geographic expansion, its effective population size increased sharply post-pandemic—

more than 1,000-fold in 2024 compared to 2021 (**figure 4E**).

Compared to its ancestor MS-MT28, the MR-MT28 clone harbours two defining mutations:

the macrolide resistance-associated A2047G mutation in the 23S rRNA gene, and a

synonymous G1959A mutation in *BP0685* (dehydrogenase/oxidase). The novel antigen allele

prn150, found predominantly in MR-MT28, was also present in one MS-MT28 strain from

Shanghai, China.

Two emerging subclones were identified within MR-MT28 (**figure 4C, D**). Subclone 1 (SC1),

estimated to have emerged around 2019, is characterised by predicted PRN deficiency, a

nonsynonymous mutation in *BP3197* (G287T; Arg96Leu; NAD(P)-dependent

oxidoreductase), and, in a subset of strains, a mutation in *BP0026* (G370T; Ala124Ser;

thiolase family protein). Notably, most (7/9) MR-MT28 strains detected in Australia and the

single French isolate belonged to SC1, suggesting enhanced transmission potential, possibly

associated with immune evasion.

Subclone 2 (SC2) harboured three distinct mutations: *BP2642A* (C664T; Pro222Ser; ABC

transporter ATP-binding protein), *BP3467* (G1621A; Asp541Asn; AsmA family protein), and

a synonymous mutation in *BP3491* (C318A; NAD(P)/FAD-dependent oxidoreductase).

Intriguingly, both subclones independently accumulated mutations in NAD(P)-dependent

oxidoreductase genes (*BP3197* in SC1 and *BP3491* in SC2), suggesting convergent

adaptation.

Discussion

The global resurgence of pertussis appears to be multifactorial, shaped by both host-related

and pathogen-related drivers.[2–7] Although the impact of host-relalted factors, such as non-

pharmaceutical interventions and waning immunity, are difficult to quantify, genomic

surveillance enables comprehensive characterisation of pathogen evolution. In this study, we

systemically analyzed all available sequences of *B pertussis* strains in the world and

compared the results with incidences of pertussis before, during and after the COVID-19

pandemic. Our findings reveal substantial or noticeable post-pandemic shifts in *B pertussis*

lineage composition, vaccine antigen profiles, and macrolide resistance across three

continents, with the most pronounced changes observed in China and Oceania.

In particular, we observed the rise of genotypes carrying mutations associated with antibiotic

resistance, vaccine escape (PRN-deficient strains), and potential increases in virulence (e.g.,

ptxP3 strains). The clearest evidence of such adaptive evolution was observed in China, where

the *ptxP3* MR-MT28 clone, encoding a novel *prn150* allele, emerged as the dominant post-

pandemic clone. This clone, capable of causing infections among older children and

vaccinated individuals, was most likely the primary driver of the post-pandemic pertussis

upsurge in China.[18,20]

Patterns of strain replacement and antigenic variation exhibited both convergent and divergent

trends across continents. First, increased MRBP prevalence and higher frequencies of the

ptxP3 and *prn150* alleles were observed in both China and Australia post-pandemic, largely

driven by the expansion of the MR-MT28 clone. Second, PRN-deficient strains declined in

prevalence in Europe, Australia, and the United States after the pandemic, accompanied by a

concurrent rise in the *prn2* allele.[31] Third, the *fim3-1* allele, already predominant before the

pandemic, further increased in frequency in China, Europe, and the United States post-

pandemic.

Region-specific trends revealed distinct adaptive trajectories. In China, the post-pandemic

resurgence was driven by the clonal expansion of MR-MT28, in contrast to the polyphyletic

strain composition observed in other regions. Notably, the prevalence of PRN-deficient strains

uniquely increased in China post-pandemic, despite being rarely reported pre-pandemic and

declining in frequency in many other countries.[11,32,33] This suggests that PRN deficiency may

confer context- and time-dependent advantages, potentially shaped by regional vaccine

formulations, the duration of vaccine use, and extent of exposure to pertussis in the

population. In Australia, the frequency of the *fim3-2* allele uniquely rose post-pandemic. This

allele had shown a global increase beginning in 1996, coinciding with the transition from

whole-cell to acellular vaccines.[30] However, its global frequency has gradually declined since

2020 for reasons that remain unclear. The *fim3-2* allele has also been reported to be associated

with enhanced biofilm formation[34]. Together, these findings may reflect region-specific

selective pressures and potential local adaptation in China and Australia.

Despite the long-standing predominance of *ptxP1* MRBP strains in China for over a decade,

they remain rarely detected elsewhere.[16–19] In contrast, *ptxP3* MR-MT28 clone has been

identified across four continents, suggesting that it may possess distinctive features

facilitating international spread. Indeed, the *ptxP3* strains appeared in Australia, Europe and

the USA in 1990s and became prevalent since then. Our genomic analysis revealed a notable

post-pandemic rise in MRBP prevalence in Australia, reaching 23% post-pandemic. This was

further supported by targeted culture-independent sequencing screening, which estimated

MRBP prevalence of 4.4%.[13] In addition to the MR-MT28 strain identified in this study from

France, a recent French study showed that overall MRBP accounted for 2.8% (17/593) of the

tests (culture and qPCR) in 2024. Phylogenetic analysis revealed that the 14 MRBP belong,

together with isolates from China, to a cluster of 349 MRBP isolates. All 14 MRBP carried

ptxP3, and 13 of them were PRN-deficient.[11,12] MRBP strains have recently been identified in

other European countries such as Finland.[33] Thus, the geographic range of MR-MT28

described here only represents a minimum estimate.

Most MR-MT28 strains detected in Australia and France were PRN-deficient, suggesting that

PRN deficiency may confer additional advantages, such as enhanced vaccine escape potential.

Together, these findings indicate that MR-MT28 represents a significant risk for global

dissemination and underscore the urgent need for strengthened international surveillance,

particularly targeting PRN-deficient MR-MT28 strains.

This study has several limitations. First, the publicly available genomic data used for

contextualisation are subject to inherent sampling biases. Since the number of genomes

available across countries and continents varies substantially, the results should be interpreted

with caution. Second, recent genomic data from several regions, particularly the United States

and parts of Europe, are limited or unavailable for comparison. Third, the number of isolates

during the pandemic is very limited, which may affect our understanding of circulating strains

during that period. Finally, vaccination programmes, vaccine types used, and non-

pharmaceutical interventions varied across countries, and the resulting selection pressures in

different populations may differ accordingly.

In conclusion, our study provides genomic evidence that the adaptive evolution of *B pertussis*,

through lineage replacement, antigenic variation, and antimicrobial resistance, has played a

significant role in the post-pandemic resurgence of pertussis. The emergence and international

dissemination of the MR-MT28 clone represent a growing public health challenge,

emphasising the need for coordinated global surveillance and updated vaccine strategies.

Contributors

P.F. and Y.C. contributed to the conception of this project. Z.R., Y.Z., P.F., Z.K., Y.Y. B.W.,

D.B., S.G., C.N., X.S., S.W., S.H. were responsible for collection of strains and metadata.

H.Z., C.Y., H.L., N.W., J.W., F.J., S.T. performed bioinformatics analysis of whole genome

sequence data. Y.C., P.F. and Q.H. prepared the manuscript. All authors contributed to the

interpretation of results and critical review of the manuscript.

Declaration of interests

We declare no competing interests.

Data sharing

Accession numbers for the publicly available genome sequences and associated metadata can

be found in appendix and Zenodo (DOI:10.5281/zenodo.15900428). Newly sequenced

genomes in this study are available from the National Centre for Biotechnology Information

database under BioProject PRJNA1288341.

Acknowledgments

This work was supported by grants from National Key Research and Development Program

of China (2022YFC2304700), National Natural Science Foundation of China (82202567,

32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences

(2022278), and Shanghai Rising-Star Program (23QA1410500), Zhejiang Provincial Science

and Technology Program for Disease Prevention and Control (2025JK139), Sigrid Juselius

Foundation (240045) and Tampere Tuberculosis Foundation (26006205).

Reference

1   Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr Opin Immunol.
2019; **59**: 72–8.

2   Domenech de Cellès M, Rohani P. Pertussis vaccines, epidemiology and evolution.
Nat Rev Microbiol 2024; **22**: 722–35.

3   Locht C. Pertussis before, during and after Covid-19. *EMBO Mol Med* 2025; **17**: 594-
598–598.

4   Kang HM, Lee T-J, Park SE, Choi S-H. Pertussis in the Post-COVID-19 Era:
Resurgence, Diagnosis, and Management. *Infect Chemother* 2025; **57**: 13–30.

5   Bricks LF, Vargas-Zambrano JC, Macina D. Epidemiology of Pertussis After the
COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the
Disease in High-, Middle-, and Low-Income Countries. *Vaccines* 2024; **12**.

6   Liu Y, Yu D, Wang K, Ye Q. Global resurgence of pertussis: A perspective from China.
Journal of Infection 2024; **89**.

7   Mengyang G, Yahong H, Qinghong M, Wei S, Kaihu Y. Resurgence and atypical
patterns of pertussis in China. *Journal of Infection* 2024; **88**.

8   Lee H, Cho UJ, Kim A-R, *et al.* Resurgence of Pertussis in the Gyeongnam Region of
South Korea in 2023 and 2024. *Vaccines* 2024; **12**.

9   Nordholm AC, Emborg H-D, Nørgaard SK, *et al.* Pertussis epidemic in Denmark,
August 2023 to February 2024. *Eurosurveillance* 2024; **29**: 2400160.

10   Monchausse T, Launay T, Rossignol L, *et al.* Clinical characteristics of cases during
the 2024 pertussis epidemic in France, January 2024 to December 2024. *Vaccine* 2025;
51: 126862.

11   Rodrigues C, Bouchez V, Soares A, *et al.* Resurgence of Bordetella pertussis, including
one macrolide-resistant isolate, France, 2024. *Eurosurveillance* 2024; **29**: 2400459.

12   Bouchez V, Lefrancq N, Toubiana J, Rodrigues C, Brisse S. Microbes know no
borders: importation of macrolide-resistant Bordetella pertussis into France in 2024.
Clinical Microbiology and Infection 2025; published online July 13.

13   Fong W, Rockett RJ, Tam KK-G, *et al.* Targeted Culture-Independent Sequencing
Identifies Emergence of Macrolide-Resistant Bordetella Pertussis in Australia.
medRxiv 2024.

14   Mooi FR, Van Loo IHM, Van Gent M, *et al.* Bordetella pertussis strains with increased
toxin production associated with pertussis resurgence. *Emerg Infect Dis* 2009; **15**.

15   Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-deficient Bordetella pertussis,
vaccine-driven evolution, and reemergence of pertussis. *Emerg Infect Dis* 2021; **27**.

16   Wu X, Du Q, Li D, *et al.* A Cross-Sectional Study Revealing the Emergence of
Erythromycin-Resistant Bordetella pertussis Carrying ptxP3 Alleles in China. *Front*
Microbiol 2022; **13**.

17   Fu P, Zhou J, Meng J, *et al.* Emergence and spread of MT28 ptxP3 allele macrolide-
resistant Bordetella pertussis from 2021 to 2022 in China. *International Journal of*
Infectious Diseases 2023; **128**: 205–11.

18   Fu P, Zhou J, Yang C, *et al.* Molecular Evolution and Increasing Macrolide Resistance
of Bordetella pertussis, Shanghai, China, 2016–2022. *Emerg Infect Dis* 2024; **30**: 29.

19   Feng Y, Chiu C-H, Heininger U, *et al.* Emerging macrolide resistance in Bordetella
pertussis in mainland China: Findings and warning from the global pertussis initiative.
The Lancet Regional Health-Western Pacific 2021; **8**: 98.

20   Fu P, Yan G, Li Y, *et al.* Pertussis upsurge, age shift and vaccine escape post-COVID-
19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China.
Clinical Microbiology and Infection 2024; **30**: 1439–46.

21   Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. *Bioinformatics* 2014; **30**: 2114–20.

22   Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: Assessing
the quality of microbial genomes recovered from isolates, single cells, and
metagenomes. *Genome Res* 2015; **25**: 1043–55.

23   Yang C, Li Y, Jiang M, *et al.* Outbreak dynamics of foodborne pathogen Vibrio
parahaemolyticus over a seventeen year period implies hidden reservoirs. *Nat*

Microbiol 2022; **7**: 1221–9.

24   Price MN, Dehal PS, Arkin AP. FastTree 2 – Approximately Maximum-Likelihood
Trees for Large Alignments. *PLoS One* 2010; **5**: e9490.

25   Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A, Wren J. RAxML-NG: A fast,
scalable and user-friendly tool for maximum likelihood phylogenetic inference.
Bioinformatics 2019.

26   Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling
trees. *BMC Evol Biol* 2007; **7**.

27   Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in
Bayesian phylogenetics using Tracer 1.7. *Syst Biol* 2018; **67**.

28   Bridel S, Bouchez V, Brancotte B, *et al.* A comprehensive resource for Bordetella
genomic epidemiology and biodiversity studies. *Nat Commun* 2022; **13**.

29   Lefrancq N, Bouchez V, Fernandes N, *et al.* Global spatial dynamics and vaccine-
induced fitness changes of *Bordetella pertussis*. *Sci Transl Med* 2022; **14**: 3253.

30   Bart MJ, Harris SR, Advani A, *et al.* Global population structure and evolution of
Bordetella pertussis and their relationship with vaccination. *mBio* 2014; **5**.

31   Barkoff AM, Mertsola J, Pierard D, *et al.* Surveillance of circulating bordetella
pertussis strains in Europe during 1998 to 2015. *J Clin Microbiol* 2018; **56**.

32   Kastrin T, Barkoff A-M, Seme K, *et al.* Pertussis epidemic in Slovenia in 2024: no
pertactin-deficient or macrolide-resistant Bordetella pertussis isolates identified.
Clinical Microbiology and Infection 2025.

33   Miettinen M, Barkoff AM, Nyqvist A, *et al.* Macrolide-resistant Bordetella pertussis
strain identified during an ongoing epidemic, Finland, January to October 2024.
Eurosurveillance 2024; **29**.

34   Niinikoski V, Barkoff AM, Mertsola J, He Q. Bordetella pertussis isolates in Finland
after acellular vaccination: serotype change and biofilm formation. *Clinical*
Microbiology and Infection 2024; **30**..

Figure legends

Figure 1. Global pertussis case numbers and incidence rates since 2000. (A) Trends in pertussis case numbers and incidence rates for the world and four continents. (B) Trends for four countries with more than ten *B pertussis* genomes from pre-, during-, and post-pandemic periods. Incidence rates are shown per 100 000 population.

Figure 2. Global population structure and resistance and antigenic profiles of *B pertussis*. (A) Annual number of high-quality genomes from four continents. (B) Maximum-likelihood phylogenetic tree of global isolates, annotated with geographic location and macrolide resistance and vaccine antigen profiles. (C) Pairwise core-genome SNP distance distributions within and between time periods (pre-, during-, and post-pandemic) for each continent and representative countries.

Figure 3. Temporal dynamics of *B pertussis* lineages (A), macrolide resistance (B), and antigenic (C) profiles. Background colours indicate different time periods (pre-, during-, and post-pandemic). Lines show the proportion of strains; point sizes indicate the number of genomes; line and point colours represent each continent or country.

Figure 4. Evolutionary dynamics and global dissemination of the MR-MT28 clone. (A, B) Geographic distribution of MR-MT28 strains post-pandemic (2023–2024), globally and within China. Pie charts indicate the regional proportion of MR-MT28. (C) Maximum-likelihood phylogeny of the MT28 clone. Tip colours represent country of origin. Outer rings denote macrolide resistance (MR or MS) and *prn* allele profiles. (D) Time-calibrated phylogeny of the MT28 clone with resistance status and *prn* allele profiles. Key time points, genetic events, and 95% confidence intervals are indicated by arrows, triangles, and shaded orange rectangles, respectively. (E) Temporal changes in the effective population size of the MT28 clone inferred using Bayesian Skygrid analysis.

Continent

| Continent | Asia | Oceania | Europe | North America |

Country

| Country | China | Australia | France | Belgium | United States |

Time-span Pre-pandemic · During-pandemic · Post-pandemic

Sample size 10–30 · 30–100 · >100

A

MR-MT28
Others

France, 1/82

United States, 1/170

China, 499/615

Australia, 9/41

B

Beijing, 3/3
Hebei, 0/1
Anhui Wuhu, 7/7
Jiangsu Wuxi, 3/3
Shanghai, 236/282
Zhejiang Jiaxing, 12/13
Zhejiang Ningbo, 142/143
Zhejiang Taizhou, 21/22
Zhejiang Yiwu, 33/63
Chengdu, 1/19
Guangdong, 41/59

C

MR-MT28
MS-MT28
Australia
France
USA
SC1
SC2

Continent
Americas
Asia
Europe
Oceania

Resistance
MR
MS

PRN
prn2
prn150
prn-others
Predicted PRN-deficient

D

Resistence
PRN

SC2
BP2642A (C664T),
BP3467 (G1621A),
BP3491 (C318A)

2016
（2014-2018)

SC1
prn-, BP3197 (G370T)

MR-MT28
23S rRNA (A2047G)
BP0685 (G1959A), prn150

2005   2010   2015   2020   2025

E

Effective population size

10^6
10^5
10^4
10^3
10^2
10
1
0.1

2010   2015   2020